Pay in 4 interest-free payments of $5.54 Learn more
Ships within 48 hours · Estimated delivery Aug 23 - Aug 28
VAT A modified fragment of human growth hormone (residues 176-191) investigated for its lipolytic properties, cartilage regeneration potential, and favorable safety profile without effects on blood glucose or IGF-1 levels
Preclinical research has examined AHK-Cu in fibroblast and dermal cell culture models for its effects on collagen and glycosaminoglycan synthesis via TGF- pathway interaction
The compound has never received market authorization in Canada or anywhere else, and Metabolic Pharmaceuticals terminated clinical development in 2007 after the Phase IIb obesity trial failed
If the safety and modest efficacy data from the published trials translate to our patient population, it would give us a tool that acts directly on fat cell metabolism rather than appetite, with a side effect profile that appears extremely well-tolerated
[3] So far, AOD9604 appears to be especially good at targeting visceral fat (the dangerous kind), because of its action in relation to beta-3 adrenergic receptors
+ - AOD-9604 generally takes 4 to 12 weeks of consistent use to produce noticeable fat-loss results
US$ 20.57
US$ 27.54
US$ 28.62
US$ 25.82
